Designing Packaging Labels For Blinded Clinical Studies: Compliance, Precision & Trial Integrity

Blinded clinical studies are widely regarded as the gold standard in clinical research, ensuring unbiased evaluation of investigational products. While study design, endpoints, and data integrity receive significant attention, one critical component often overlooked is clinical trial packaging label design.

Blinded study labels are not just informational they are regulatory tools that directly protect study integrity.

For Regulatory Artwork Teams, designing these labels requires a precise balance between:

• Compliance with global regulations 
• Preservation of the blind 
• Accurate traceability 
• Operational usability 

At Maven Regulatory Solutions, we specialize in delivering audit-ready, globally compliant clinical trial labels that maintain blinding while supporting complex, multi-country studies.

Why Clinical Trial Labels Are Critical in Blinded Studies

Unlike commercial packaging, which focuses on branding and differentiation, blinded clinical labels must achieve the exact opposite complete uniformity and neutrality.

Even minor visual differences such as:

• Slight font variation 
• Ink shade differences 
• Layout inconsistencies 

can unintentionally unblind a study, compromising years of research and regulatory validity.

Core Objectives of Blinded Label Design:

• Preserve the blind: Ensure identical appearance across all study arms 
• Enable safe handling: Provide clear instructions for investigators and pharmacists 
• Ensure traceability: Link product to patient and protocol without revealing identity 
• Maintain compliance: Align with global regulatory requirements 
• Manage dynamic data: Handle expiry dates, batch numbers, and kit IDs securely 

Regulatory Framework for Clinical Trial Labeling

Blinded clinical trial labels must comply with multiple global regulatory authorities, including:

• U.S. Food and Drug Administration 
• European Medicines Agency 
• Medicines and Healthcare products Regulatory Agency 
• Health Canada 

Key Regulatory Expectations:

• No disclosure of treatment allocation 
• Clear investigational use statements 
• Accurate protocol identification 
• Patient safety instructions 
• Multilingual compliance where applicable 

The Label Design Lifecycle

Designing labels for blinded clinical trials is a multi-step, cross-functional process involving regulatory, clinical, and operational teams.

1. Requirement Gathering

• Review clinical protocol 
• Identify regulatory requirements by region 
• Align with sponsor and CRO expectations 

2. Neutral Text Development

• Use non-identifying terminology (e.g., “Study Medication”) 
• Avoid brand or active ingredient disclosure 
• Include essential information: 
  • Protocol number 
  • Dosage instructions 
  • Expiry date 
  • Storage conditions 

3. Secure Coding & Randomization

• Integration of: 
  • Randomization codes 
  • Unique kit identifiers 
  • Barcodes/QR codes 

These ensure traceability without revealing treatment allocation.

4. Artwork Design & Mockups

• Standardized layouts across study arms 
• Consideration of: 
  • Label size and packaging type 
  • Booklet labels vs peel-off labels 
  • Country-specific requirements 

5. Regulatory & Translation Review

• Multilingual label adaptation 
• Compliance checks against: 
  • Regional labeling laws 
  • Clinical trial regulations 

6. Cross-Functional Quality Checks

• QA verification 
• Clinical validation 
• Alignment with study protocol 

7. Proofing, Version Control & Approval

• Electronic proofing systems 
• Controlled version tracking 
• Formal approval workflows 

8. Printing & Packaging Execution

• Just-in-time label printing 
• Serialization and batch tracking 
• QA oversight to ensure blind integrity is maintained 

Key Design Considerations

Label Formats in Blinded Trials

Different study designs require different label formats:

• Booklet Labels: Ideal for multilingual content 
• Peel-Off Labels: Enable dispensing and documentation 
• Over labels: Used for blinding commercially available products 

Each format must maintain visual uniformity across all treatment arms.

Common Pitfalls in Blinded Label Design

Even experienced teams can encounter risks:

1. Visual Differentiation

• Different label sizes or layouts
• Solution: Use identical templates across all arms 

2. Language Imbalance

• Uneven text distribution in multilingual labels
•  Solution: Apply mirrored formatting structures 

3. Visible Identifiers

• Batch or product-specific information exposed
•  Solution: Encode data within barcodes 

4. Version Control Errors

• Outdated label versions used in production
• Solution: Implement centralized artwork management systems 

Advanced Trends in Clinical Trial Labeling

• Digital artwork management platforms 
• AI-assisted proofreading and compliance checks 
• Smart labeling with QR codes for real-time data access 
• Integration with Interactive Response Technology (IRT) systems 
• Increased focus on patient-centric label design 

Why This Matters

A single labeling error in a blinded study can lead to:

• Study unblinding 
• Regulatory non-compliance 
• Data integrity issues 
• Costly delays or trial termination 

On the other hand, robust label design ensures:

• Regulatory approval readiness 
• Patient safety 
• Reliable clinical outcomes 

Why Sponsors Choose Maven Regulatory Solutions

Our Expertise:

• Global experience across Phase I–IV clinical trials 
• Deep regulatory knowledge across US, EU, UK, Canada, and APAC 
• Advanced artwork and labeling systems 
• Multilingual label development and proofreading 

Our Capabilities:

• End-to-end label design and lifecycle management 
• Serialization and traceability solutions 
• Rapid turnaround within tight study timelines 
• Audit-ready documentation and compliance 

Strengthen Your Clinical Trial Labeling Strategy

Running blinded clinical trials?

Partner with Maven to:

• Protect study integrity 
• Ensure global compliance 
• Deliver high-quality, audit-ready labeling 

Conclusion

In blind clinical trials, packaging labels are far more than simple identifiers they are critical safeguards of study integrity.

From maintaining the blind to ensuring compliance and traceability, every design decision plays a vital role in trial success.

As clinical trials become increasingly global and complex, sponsors need partners who understand the intersection of regulatory science, design precision, and operational execution.

Maven Regulatory Solutions delivers exactly that help you create labels that are compliant, consistent, and built to protect your study at every stage.

FAQs

1. What is a blinded clinical trial label?

A label designed to conceal treatment identity while providing necessary information.

2. Why is label uniformity important?

To prevent unblinding and maintain study integrity.

3. What information must be included?

Protocol number, dosage, expiry date, and safety instructions.

4. How is traceability maintained?

Through coded identifiers and barcodes.

5. What are common label formats?

Booklet, peel-off, and over labels.

6. Which regulations apply?

FDA, EMA, MHRA, and other regional authorities.

7. How can Maven help?

By delivering compliant, audit-ready, blinded study labels.